China Securities Index Co., Ltd. decided to revise the China Securities Full Index Pharmaceutical Index preparation plan. This revision includes: (1) the index name was revised to “China Securities Pharmaceutical Index”; (2) the investability screening conditions were revised to rank in the top 90% of the sample space for the average daily turnover in the past year; (3) the index base date was revised to 2011/12/30; (4) the sample selection method was revised to select the top 50 securities in total daily market value over the past year from the securities of listed companies involved in traditional Chinese medicine, chemicals, and biopharmaceuticals as index samples; (5) the weighting method was revised to no more than 15% for a single sample, and the total weight of the top five samples did not exceed 60%. The rest of the index development programme remains unchanged. The revisions to the above preparation plan will be implemented on October 30, 2023.